Literature DB >> 6343092

Characteristics of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody.

M R Price, D G Campbell, R A Robins, R W Baldwin.   

Abstract

The expression of a cell surface antigen defined by an anti-human osteogenic sarcoma monoclonal antibody was analysed by flow cytofluorometry using fluorescein-labelled antibody. Quantitative absorption tests established that the antigen was associated with plasma membranes, whereas cytosol, cellular lipids and nuclei were largely devoid of activity. Single-phase aqueous butanol solutions at non-cytolytic concentrations failed to solubilize the antigen, although treatment of cells with papain virtually abolished antigenic activity. The antigen was shown to be solubilized by the non-ionic detergent Nonidet P-40, and following lactoperoxidase-catalysed radioiodination of viable cells, extraction with detergent, immunoprecipitation of antigen with monoclonal antibody and Sepharose-Protein A, the molecular weight of antigen was determined by sodium dodecyl sulphate-polyacrylamide gel electrophoresis. The findings indicate that this human osteogenic sarcoma antigen is a monomeric integral membrane protein with an apparent molecular weight of 72,000, which is predominantly expressed at the external face of the tumour cell plasma membrane.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6343092     DOI: 10.1016/0277-5379(83)90402-9

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  13 in total

Review 1.  Monoclonal antibodies. Future potential in cancer chemotherapy.

Authors:  C Kosmas; H Kalofonos; A A Epenetos
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

2.  Humoral immune responses to XMMCO-791-RTA immunotoxin in colorectal cancer patients.

Authors:  L G Durrant; V S Byers; P J Scannon; R Rodvien; K Grant; R A Robins; R A Marksman; R W Baldwin
Journal:  Clin Exp Immunol       Date:  1989-02       Impact factor: 4.330

3.  Localization of anti-osteogenic sarcoma monoclonal antibody 791T/36 in a primary human osteogenic sarcoma and its subsequent xenograft in immunodeprived mice.

Authors:  M V Pimm; A C Perkins; N C Armitage; R W Baldwin
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

4.  The localization of anti-tumour monoclonal antibodies in colorectal cancer.

Authors:  N C Armitage
Journal:  Ann R Coll Surg Engl       Date:  1986-11       Impact factor: 1.891

5.  Selective extraction by 1-butanol of surface glycoprotein antigens from human melanoma cells.

Authors:  S K Liao; J W Smith; P C Kwong
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

6.  Expression of monoclonal-antibody-defined antigens in fractions isolated from human breast carcinomas and patients' serum.

Authors:  M V Croce; M R Price; A Segal-Eiras
Journal:  Cancer Immunol Immunother       Date:  1995-02       Impact factor: 6.968

7.  Immunolocalization of the murine monoclonal antibody, 791T/36 within primary human colorectal carcinomas and identification of the target antigen.

Authors:  M R Price; M V Pimm; C M Page; N C Armitage; J D Hardcastle; R W Baldwin
Journal:  Br J Cancer       Date:  1984-06       Impact factor: 7.640

8.  Enhanced recognition of human colorectal tumour cells using combinations of monoclonal antibodies.

Authors:  L G Durrant; R A Robins; K C Ballantyne; R A Marksman; J D Hardcastle; R W Baldwin
Journal:  Br J Cancer       Date:  1989-12       Impact factor: 7.640

9.  Antigenicity and drug susceptibility of human osteogenic sarcoma cells "escaping" a cytotoxic methotrexate-albumin-monoclonal antibody conjugate.

Authors:  M J Embleton; M C Garnett; E Jacobs; R W Baldwin
Journal:  Br J Cancer       Date:  1984-05       Impact factor: 7.640

10.  Sensitivity of newly established colorectal cell lines to cytotoxic drugs and monoclonal antibody drug conjugates.

Authors:  L G Durrant; M C Garnett; J Gallego; N C Armitage; K C Ballantyne; R A Marksman; J D Hardcastle; R W Baldwin
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.